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Abstract
The study of membrane protein structure and function requires their high-level expression and purification in fully
functional form. We previously used a tetracycline-inducible stable mammalian cell line, HEK293S-TetR, for regulated high-
level expression of G-protein coupled receptors. We here report successfully using this method for high-level expression of
de novo oligo-DNA assembled human CD81 gene. CD81 is a member of the vital tetraspanin membrane protein family. It
has recently been identified as the putative receptor for the Hepatitis C Virus envelope E2 glycoprotein (HCV-E2). In this
study we used a single-step rho-1D4-affinity purification method to obtain .95% purity from HEK293S-TetR-inducible
stable cell lines. Using ELISA assay we determined that the affinity of the purified CD81 receptor for HCV-E2 protein is
3.861.2 nM. Using fluorescent confocal microscopy we showed that the inducibly overexpressed CD81 receptor in
HEK293S-TetR cells is correctly located on the plasma membrane. We demonstrated that the combination of high-level
expression of CD81 with efficient single-step immunoaffinity purification is a useful method for obtaining large quantities of
CD81 membrane receptor suitable for detailed structural analyses of this elusive tetraspanin protein. Furthermore, this
simple single-step immunoaffinity purification to high purity of membrane protein could be useful broadly for other
membrane protein purifications, thus accelerating the determination of structures for large numbers of difficult-to-obtain
membrane proteins.
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Introduction
Recently enormous advancement has been made in high-
resolution protein structural determinations, there are more than
50,000 protein structures and protein-complexes currently avail-
able in the Protein Data Bank (http://www.rcsb.org/pdb/home/
home.do). However, except a few hundred minorities, almost of all
the structures are soluble proteins.
It is known that membrane proteins are vital family proteins in
all living systems. This is evident that ,30% genes in almost all
sequenced genomes code for membrane proteins [1–3]. However,
our understanding of structures and functions of the membrane
proteins lag far behind the known soluble proteins. As April 2008,
there are only 157 unique membrane protein structures known
among their variations of 368 total membrane proteins [http://
blanco.biomol.uci.edu/Membrane_Proteins_xtal.html]. One of
the reasons of lacking membrane protein structures is largely
due to the notoriously difficult steps to purify large quantity of
stable and functional membrane proteins. In order to accelerate
membrane protein structural studies, new and simple methods are
crucial.
A very interesting and important class of integral membrane
proteins is tetraspanins, which is a diverse family that comprises
four transmembrane (TM) helices [4,5]. Biochemical and
bioinformatics analyses suggest that TM helix 1 is linked to TM
helix 2 by a small extracellular loop (SEL). TM helix 3 is linked to
TM helix 4 by a rather large extracellular loop (LEL) while an
intracellular loop connects TM helices 2 and 3 [6,7]. The LEL
loop which contains four to eight cysteines and a signature Cys-
Cys-Gly motif distinguishes the tetraspanins (Fig. 1) from other
membrane proteins having four TMs. Although tetraspanins are
widely distributed, occurring in most animal tissues and have been
shown to be involved in essential cellular and physiological
functions including cell proliferation, activation and signaling
[4,5,7], its detail molecular structure remains largely elusive.
Human CD81 that belongs to a member of the tetraspanin
family has been identified as the putative receptor for the Hepatitis
C Virus envelope E2 glycoprotein (HCV-E2) [8–10]. Hepatitis C
Virus is one of the leading causes of chronic liver diseases.
According to a World Health Organization report, ,3% of the
human population is infected by HCV (WHO, 2002). Previously it
has been shown that a recombinant soluble portion of CD81,
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designated CD81-LEL, binds to HCV-E2 with an affinity of
1.8 nM [8]. However, structural information on members of the
tetraspanin family is rather limited. Of the relevant two studies,
one reported on a high-resolution crystal structure of the CD81-
LEL soluble domain fragment at 1.6A˚ [11], while a Cryo-Electron
Microscopy (cryo-EM) study described a 6A˚ resolution structure of
the entire tetraspanin, uroplakin [6]. The cryo-EM study of
uroplakin suggests that both the transmembrane and extracellular
domains of uroplakins are involved in interaction with other
transmembrane proteins of the tetraspanin network.
Lack of a high-resolution structure for an entire tetraspanin is
due to the lack of an expression system for preparation of the
integral membrane protein in large quantity required for structural
studies using protein X-ray crystallography or NMR spectroscopy.
We previously reported the use of a tetracycline-inducible stable
mammalian cell line (HEK293S-TetR) system for high-level
expression of two G-protein coupled receptors (GPCR) of
rhodopsin and b2-adrenergic receptor [12,13]. We reasoned that
we could use the same system to obtain large quantity of the
elusive tetraspanin CD81. Here we report the successful use of this
overexpression system with mammalian cell line for the high-level
expression of CD81. We made a codon-optimized oligo-DNA/
PCR synthesized gene, constructed a stable HEK293S-TetR cell
line and inducibly expressed the gene. After high-level expression,
we finally purified the CD81 protein using a single-step rho-1D4-
affinity to near homogeneity. The yield of CD81 as visualized on
immunoblots was ,26 mg/36107 cells per 15 cm tissue culture
plate. By using an ELISA assay, the affinity of the purified CD81
receptor for HCV-E2 protein was estimated to be 3.861.2 nM.
This simple assay, which involves in coating of the rho-1D4-
antibody on ELISA plates followed by immobilization of CD81,
will have applications for high-throughput screening (HTS) of
libraries of small molecule inhibitors of CD81. Biochemical
analysis of the purified CD81 showed no detectable post-
translational modifications including N- and O-glycosylations that
are normally found in other tetraspanin membrane proteins
expressed in mammalian cells.
Results and Discussion
Designed gene and mammalian overexpression
The codon optimized synthetic DNA corresponding to the
human CD81 gene comprises 776 base-pairs of which 744 base-
pair represents the open reading frame (Fig. S1). The design and
synthesis of this gene is described in the Methods section. To
ensure tightly regulated high-level expression of this potentially
toxic CD81 gene, stable cell lines of CD81 were constructed using
the HEK293S-TetR inducible system. A total of 32 independent
clones were examined for the expression of CD81 using a dot-blot
immuno-detection method. The cell line that showed the highest
protein expression was selected for further studies. HEK293S-
TetR cells expressing the synthetic CD81 gene were grown as
monolayers in 15 cm tissue culture dishes. After induction with
tetracycline and sodium butyrate for ,44–48 hours, the cells were
Figure 1. Schematic illustration of a two-dimensional model of human CD81 membrane receptor. The extracellular domain contains two
loops, the small extracellular loop (SEL) and large extracellular loop (LEL). The CD81 receptor contains the rhodopsin C-terminal 9-residue peptide
sequence (shown underlined) at its C-terminus as the tag to facilitate detection and purification of the membrane protein using the monoclonal
antibody rho-1D4.
doi:10.1371/journal.pone.0002314.g001
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collected by centrifugation and the cell pellet was quick-frozen and
stored at 280uC until purification. After induction, a relatively
high binding of anti-CD81 antibody on the cell surface of
HEK293S-TetR detected using cellular ELISA assay (data not
shown) indicated the presence of overexpressed CD81 on the
plasma membrane.
Single-step immuno-affinity purification of CD81
membrane protein
For receptor purification, cell membranes were prepared from the
cell pellet and solubilized using buffer B as described in Materials
and Methods. The receptor purified using the rho-1D4-Sepharose
beads was .95% purity as determined by SDS-PAGE and silver
staining (Fig. 2A). The yield of CD81 following the single-step rho-
1D4-Sepharose affinity purification was determined by semi-
quantitative immuno-detection using the signal generated by known
amounts of rhodopsin (isolated from bovine retina) for calibration
(Fig. S2). This quantitative method of protein concentration showed
the expression of CD81 to be ,26 mg/36107cells per 15 cm tissue
culture plate. While this level of expression is one of the highest
reported so far for the total CD81 receptor using mammalian cell,
previous studies on the expression of soluble CD81-LEL in Escherichia
coli using a GST-LEL fusion tag reported expression level of up to
3 mg/L, and achieved a purification of .95% using four step
purification procedures [10].
Characterization of purified CD81 tetraspanin membrane
protein
The purified CD81 migrated as a single band at around 27kDa
on 16% SDS-PAGE (Fig. 2A). To separate the nonapeptide from
the eluted pure protein, the purified CD81 was concentrated using
a 10-kDa cut off membrane (Amicon YM-10). However, MALDI-
TOF mass analysis of the purified protein after desalting showed a
mass of 28,153 Daltons (Fig 3), indicating a discrepancy of 1,345
Daltons between the observed and the theoretical mass, 26,808
Daltons. The extra mass could be due to the presence of the non-
ionic detergent remaining bound or interacting to the protein or
might be due to other post-translational modifications. The N-
terminus of the purified protein was confirmed by N-terminal
sequencing to have the amino acid sequence M/G, G/V, V/E, E/
G, and G and since the C-terminus of the protein carried the rho-
1D4 affinity tag, this confirmed the purified CD81 to be the full
length protein. Further, the observed discrepancy in mass is not
uncommon among the tetraspanins, with a recent report showing
the theoretical mass of CD9 to be 25 kDa while the observed mass
was found to be 27kDa [14].
The extracellular sequence of CD81 lacks the consensus N-
glycosylation motif, Asn-xxx-Ser/Thr, thus as expected, the
receptor expressed in the HEK293S-TetR stable cell line did
not appear N-glycosylated because its migration on SDS-PAGE
was unaltered even after treatment with N-glycanase PNGaseF
(Fig 2B). This result is in agreement with previous observation that
CD81, unlike other tetraspanins, is unglycosylated [15]. The
possibility that CD81 had other post-translational modification,
such as O-glycosylation (O-GlcNAc), was investigated. Immuno-
blottting of CD81 followed by probing of the blot with the highly
specific mouse monoclonal antibody for the detection of the O-
GlcNAc post-translational modification (see Methods) showed that
CD81 did not have any O-GlcNAc (Fig 2C).
Sub-cellular localization of CD81 in HEK293S cells
Since we made the synthetic CD81 membrane protein gene, we
are interested if CD81 is functional and indeed localizes on the cell
plasma membrane. We therefore carried out experiments to
determine the sub-cellular localization of CD81 expressed in the
inducible HEK293S stable cell lines using confocal fluorescent
microscopy. We examined the sub-cellular distribution of CD81 in
the HEK293S-TetR cells, before and after induction with
tetracycline and sodium butyrate, using rho-1D4 antibody for
immunofluorescence staining (see Methods). We found that the
overexpressed CD81 was mainly localized at the cell surface (Fig. 4)
with only minimal amounts, presumably in-transit, present
intracellularly. This localization result is a strong indication of
correct folding of CD81 because misfolded membrane proteins are
retained in the ER by the highly effective ER quality control
Figure 2. Affinity purification of CD81 receptor. A) SDS-PAGE
(16%) of the solubilized (Lane 1) and rho-1D4-affinity purified CD81
(Lane 2). Proteins were detected by silver staining. Lane 1, 2.5 mg of
solubilized membrane protein, Lane 2, 0.5 mg of rho-1D4-purified
receptor. Lanes 3 and 4 represent the immunoblot analysis of the same
samples as in lanes 1 and 2, but same volume fraction of each
solubilized and purified sample (1/7000) was loaded. Immunoblot
analysis was done using the monoclonal antibody rho-1D4 (the epitope
tag for this antibody was added to the C-terminal tail of CD81 gene).
Mobility of molecular weight standards is indicated next to the gel. B)
Immunoblot analysis of PNGaseF treated (Lane 1) and an untreated
(Lane 2) sample of CD81, 1 mg of total solubilized protein is loaded in
each lane. C) Immunoblot analysis of CD81, with a highly specific
mouse monoclonal antibody for the detection of O-GlcNAc post-
translational modification. As a positive control, O-b-GlcNAc-modified
BSA (5 ng), which runs as a 66kDa band, is loaded in lane 1. In lane 2,
1 mg of total solubilized CD81 protein is loaded.
doi:10.1371/journal.pone.0002314.g002
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system [16]. Owing to the tight repression by tetR protein, in the
absence of the inducers, tetracycline and sodium butyrate,
HEK293S-TetR cells harboring the CD81 gene did not show
detectable fluorescent signal from leaky expression of CD81 gene.
Affinity of purified CD81 for HCV-E2 binding assay
Measuring the binding affinity of CD81-LEL to HCV-E2
glycoprotein is an established method to characterize the
functional integrity of CD81. While most of the preceding studies
have used only the LEL-fragment of CD81 to characterize HCV-
E2 binding, here we used the entire purified detergent DM-
solubilized CD81 receptor and measured its affinity towards
HCV-E2 in an in vitro assay. In this assay CD81 was oriented to
favor binding to HCV-E2, accomplished by coating the plates with
rho-1D4 antibody (Fig. 5A). The epitope tag for this antibody is
present at the C-terminus of CD81 so that the extracellular region
of CD81 is free for binding to HCV-E2. Using this assay, the
affinity between the purified CD81 and HCV-E2 was found to be
3.861.2 nM (Fig. 5B), a value close to the previously reported
affinity, 1.8 nM, between CD81-LEL and HCV-E2 [5]. The
observed difference in affinity could be due to the fact that the
entire CD81 was used as only a water-soluble fragment CD81-
LEL, which could have fold differently and could have tendency of
binding with more exposed conformation. Also, the presence of
the detergent DM could influence the affinity of the interaction.
However, it is plausible our measurement is closer to the cellular
CD81 receptor binding affinity to HCV-E2 when measured both
with the entire receptor protein and in the presence of membrane
protein-stabilization detergent.
Biomedical application of the affinity purified CD81
One of the possible applications of this study is to enable high-
throughput screening (HTS) to rapidly identify inhibitors for
CD81-HCV-E2 binding. A prerequisite for this step is the
availability of obtaining large quantity of highly purified CD81,
Figure 3. MALDI-TOF mass analysis of anti-rho-tag affinity-purified CD81 receptor membrane protein. The peak at 28,153 daltons
corresponds to the purified CD81. The sample is internally calibrated using a standard, which is observed as a peak at 33,216 daltons.
doi:10.1371/journal.pone.0002314.g003
Figure 4. Localization of CD81 overexpressed in HEK293S-TetR
cell line. Following induction of cells harboring HEK293S-TetR-CD81,
the cells were fixed with formaldehyde, and permeabilized with 0.05%
Triton X-100. Dual immuno-fluorescence was performed with mouse
rho-1D4 antibody and rabbit anti-cadherin antibody (A) or anti-calnexin
antibody (B), which were localized at the plasma membrane and ER,
respectively. Mouse rho-1D4 antibody was visualized with Alexa 647
anti-mouse secondary antibody (red), and rabbit anti-cadherin and
calnexin antibody was visualized with Alexa 488 anti-rabbit secondary
antibody (green). Overexpressed CD81-rho-1D4 was localized at the
plasma membrane (merge), while endogenous CD81-rho-1D4 was not
observed without induction (control).
doi:10.1371/journal.pone.0002314.g004
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as we have now demonstrated. Furthermore, immobilization of
CD81 receptor at the C-terminus using rho-1D4 antibody ensures
that the E2 binding site (CD81-LEL) remains fully accessible.
Several surface modification techniques such as polymer coating,
site-directed immobilization and gel network are available to
maximize the binding capacity of surface-coating protein (rho-1D4
antibody in this study) and to immobilize in favorable orientation,
and prevent denaturation during immobilization [17].
A well-structured 3D surface rather than a 2D surface can also
be microfabricated to significantly increase the surface area to
sample volume ratio [18]. In addition, miniaturization of reaction
space significantly decreases the sample volume which, in turn,
reduces the reaction time to reach equilibrium [19]. These
improvements utilizing multidisciplinary techniques such as,
surface chemistry, microfluidics and microfabrication [19],
combined with membrane protein biochemistry offer promise to
improve sensitivity and reproducibility for HTS.
We have developed an efficient system for the functional
expression with mammalian cell line and a single-step immunoaf-
finity purification of human CD81 tetraspanin membrane
receptor. Using this system, purification of the receptor in
milligram to gram quantities is now feasible using suspension
culture in a large bioreactor. Production of CD81 at such high-
levels will not only enable detailed structural analysis of this elusive
family of integral tetraspanin membrane proteins, but also allow
biotechnological advancement to immobilize CD81 on several
formats of solid supports for drug discovery and disease diagnosis
to combat HCV infectious liver diseases.
A useful and simple method for obtain large quantity of
membrane proteins
The combination of using rhodopsin affinity 9-residue motif to
tag onto other membrane proteins and using anti-rho-tag antibody
as the affinity purification method could have far reaching
implications for quickly obtaining large quantity membrane
proteins. We have also applied this simple method to purify large
quantities of several de novo assembled human and mouse olfactory
receptor proteins. The methods we reported here demonstrated
that this simple single-step immunoaffinity purification to
extremely high purity could be useful broadly for other membrane
protein purifications, thus accelerate determination of the
structures of large number of difficult-to-obtain membrane
proteins.
Materials and Methods
Materials
Synthetic oligonucleotides were purchased from IDT (Coral-
ville, IA). Sepharose 4B was purchased from Sigma (St.Louis,
MO). The detergent n-dodecyl-b-D-maltoside (DM) was pur-
chased from Anatrace (Maumee, OH). The monoclonal antibody,
rho-1D4, was prepared by the Cell Culture Center (Minneapolis,
MN) from a cell line provided by R.S. Molday (University of
British Columbia, Vancouver, Canada). FBS and tetracycline were
purchased from Sigma, and sodium butyrate was from J. T. Baker
(Phillipsburg, NJ). Ham’s F-12/DME High Glucose was from
Irvine scientific (Santa Ana, CA). Geneticin (G418), Blasticidin S-
HCl was from Invitrogen (Carlsbad, CA). Protease inhibitors and
common chemicals were purchased either from Sigma or
Invitrogen. Restriction enzymes and PNGase F were purchased
from New England Biolabs (Ipswich, MA). The 9-residue peptide
corresponding to the C-terminal sequence of rhodopsin, which
was used to elute CD81 from the antibody rho-1D4 sepharose
matrix, was synthesized at the MIT-Biopolymers Laboratory
(Cambridge, MA).
Immulon ELISA plates were from Santa Cruz (Santa Cruz,
CA). ELISA amplification system is from Invitrogen. Rabbit anti-
cadherin and calnexin polyclonal antibody, Goat anti-human
Hepatitis C Virus E2 polyclonal antibody and Rabbit anti-goat
IgG with alkaline phosphatase conjugate was from Abcam
(Cambridge, MA). Recombinant HCV E2 envelope protein was
from Immuno Diagnostics (Woburn, MA). Ultrablock (blocking
solution) was from Serotec (Raleigh, NC). BioCoat Collagen I 8-
well culture slide was from BD Falcon (Franklin Lakes, NJ). Image-
iT FX Signal enhancer, Alexa Fluor 488 goat anti-rabbit antibody
and 647 goat anti-mouse antibody were from Invitrogen.
Buffers used were as follows: PBS buffer: 137 mM NaCl,
2.7 mM KCl, 1.8 mM KH2PO4, 10 mM Na2HPO4 (pH 7.4);
Buffer A (Lysis buffer), 10 mM Tris-HCl, pH 7.4, containing
protease inhibitors (1 mM EDTA, 10 mg/ml benzamidine, 10 mg/
ml leupeptin, 20 mg/ml soybean trypsin inhibitor, 5 mg/ml
aprotinin, and 0.2 mM phenylmethylsulfonyl fluoride); Buffer B
(Solubilization buffer), 20 mM Tris- HCl, pH7.4, containing
500 mM NaCl, 10% glycerol, 1% DM and the protease inhibitors
as in buffer A; Buffer C (High-salt buffer), 20 mM Tris-HCl,
pH7.4 containing 500 mM NaCl; Buffer D (TBS buffer), 25 mM
Tris-HCl, pH 7.5 containing 144 mM NaCl.
Figure 5. Binding affinity of purified CD81 for HCV-E2. A)
Schematic showing the methodology of the ELISA assays using rho-1D4
antibody and purified CD81 receptor. B) ELISA plates were coated with
rho-1D4 monoclonal antibody and purified CD81 was added, followed
by the addition of increasing concentrations of HCV-E2 from 0.4 to
20 nM (assay was carried out as described in Materials and Methods).
Specific binding expressed as percentage, was derived by subtracting
nonspecific binding (binding in the absence of rho-1D4) from the total
binding. Binding data were obtained from a minimum of two
independent determinations done in duplicate and are shown as
mean6S.E. Data were analyzed by non-linear regression using PRISM
software (Graph Pad Software, San Diego, CA).
doi:10.1371/journal.pone.0002314.g005
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Methods
Synthesis, cloning and stable cell line construction of
human CD81 gene. The synthetic CD81 gene consisted of
776bp, of which the 744bp encodes CD81-GlyGly-rho-1D4. The
salient features of the codon optimized CD81 gene include, a
Kozak consensus (GCCACCATGG) 59 of the ATG start codon
[20], a two amino acid long glycine spacer and the bovine
rhodopsin C9 epitope tag (TETSQVAPA) immediately 59 to the
natural stop codon of CD81, and restriction sites for EcoRI at the
59 end and NotI at the 39 end to facilitate cloning into expression
vectors. The sequence encoding the human CD81 gene (NCBI
Accession # BC002978) was optimized for mammalian codon
usage by utilizing the codons predicted to occur frequently in
highly expressed genes of mammals [21]. PCR primers were
designed using DNAWorks [22] http://mcl1.ncifcrf.gov/
dnaworks/dnaworks2.html. A total of 40 oligonucleotides were
synthesized at 25 nmol scale with the sense strand (referred as SS)
and the antisense strand (referred as AS) consisting of 20
oligonucleotides each (Table S1). Construction of the human
CD81 gene and its cloning into the pACMV-tetO vector [12] and
the subsequent construction of HEK293S tetracycline inducible
stable cell lines was similar to what has been reported before for
beta2-adrenergic receptor [13], except the PCR program for gene
synthesis consisted of 30 cycles.
Localization of overexpressed CD81. Changes in CD81 cell
localization after induction was measured using confocal
microscopy. HEK293S-TetR-CD81 cells were cultured on BD
BioCoat culture slides, 24 hours or 48 hours after induction the wells
were washed with 16PBS, and then fixed in 3.7% formaldehyde/
16 PBS for 15 min at room temperature. The cells were then
permeablized with 0.05% triton X-100/16PBS for 30 min at room
temperature. The permeablization buffer was then washed out with
16 PBS, the cells blocked with Signal Enhancer (Invitrogen),
blocking solution, incubated with the primary antibody (mouse rho-
1D4, rabbit anti-cadherin, rabbit anti-calnexin) in 10% FBS/16
PBS for 1 hour at room temperature, washed, incubated with a
fluorescent coupled secondary antibody (Alexa FluorTM 488 goat
anti-rabbit , Alexa FluorTM 647 goat anti-mouse), washed twice,
then covered with coverglass and nail polish. The slides were
visualized using Radiance 2100 MP laser confocal microscope and
LaserSharp 2000 software (Bio-Rad). Images were processed using
ImageJ (NIH, Bethesda, MD).
Purification of CD81 by rho-1D4 affinity chromato-
graphy. Tetracycline inducible HEK293S stable cell lines
expressing CD81 were grown to confluence in 15 cm dishes and
expression of CD81 was induced by adding 1 mg/ml tetracycline
and 5 mM sodium butyrate. Following induction for 44 hours, the
dishes were rinsed, using ice-cold PBS buffer and the cells were then
harvested in buffer A. All further steps were carried out at 0u to
+4uC. The cell suspension was next transferred into a 15 ml dounce
tissue homogenizer and the cells were homogenized using 15 strokes.
The cell homogenate was centrifuged at 48,0006 g for 20 min at
4uC. The resulting membrane pellet was snap frozen in liquid
nitrogen and stored at 280uC until required. The protein
concentration in the resuspended membrane pellet was
determined using DC protein assay kit from Bio-Rad Laboratories
(Hercules, CA). Cell pellets from 10 to 40 dishes (15 cm), were
resuspended using buffer B, and the suspension was further
homogenized using a dounce homogenizer (15 strokes). The
solubilized CD81 receptor was adsorbed to rho-1D4-Sepharose
beads in batch mode (binding capacity corresponding to 1 mg
rhodopsin/ml of beads) with slow agitation for 2–4 h at 4uC. The
rho-1D4-beads were then collected by centrifugation at 1,500 g and
washed with buffer C until the absorbance of the wash at 280 nm
was below 0.01. Elution was carried out with buffer C containing
100 mM nonapeptide. The receptor appeared in the elution,
following elution with 2-bed volumes of the eluant. Elution
samples were concentrated by using Amicon YM-10 (Millipore,
Bedford, MA). The protein concentration was determined by
BioRad DC protein assay.
Quantitation of CD81 by Immunoblots. The total amount
of CD81 receptor obtained by the single-step affinity purification was
determined by using quantitative immunoblot analysis. For these
assays, known amounts of purified bovine rhodopsin (200, 400, 600,
800 and 1000 pg) were used to generate a standard curve. CD81
purified as described above was diluted in PBS buffer containing
0.05% DM, to achieve a dilution within the range of the standards.
Protein samples were resolved by 12% SDS-PAGE gel. The protein
was then transferred from the gels onto a nitrocellulose membrane
by electroblotting and CD81 along with bovine rhodopsin was
visualized by immuno-detection with the monoclonal antibody, rho-
1D4 followed by incubation with HRP-linked anti mouse IgG and
ECL. The strength of chemiluminesence signal on the blots was
quantified either by a phosphoimager or visualized by using Kodak
X-OMAT film. The pixel density was determined using Scion Image
for Windows (Scion Corporation, Frederick, MD). The data were fit
using a linear regression algorithm in Sigma plot v8.0 (SPSS Science,
Chicago, IL).
Glycosylation analysis. Cell membranes containing CD81
were solubilized with 1% DM and were treated with PNGaseF
and incubated for 1 h at 37uC. Separation of reaction products are
visualized by SDS-PAGE. The presence of O-linked glycosylation
(O-GlcNAc) was determined by immunoblot analysis using the O-
GlcNAc Western Blot Detection system from Pierce (Rockford,
IL), and according to the directions supplied by the manufacture.
As a positive control, O-GlcNAc-modified BSA, which runs at
approximately 66 kDa, was used (Fig. 2C).
Mass spectrometry and N-terminal sequencing. The
MALDI-TOF spectra analysis of the rho-1D4 purified CD81
sample was conducted by the MIT Biopolymers laboratory. Briefly,
purified CD81 was concentrated using Amicon YM-10 to 0.25 mg/
ml concentration and processed using a Zip-Tip. The sample was
then reconstituted in 4 ml of 50% ACN/0.1% TFA. Then, 3 ml of
the sample was dried down, reconstituted in 1 ml of matrix (sinapinic
acid), and mass spectra were obtained in linear mode. The sample
was internally calibrated using a standard, which was observed as a
peak at 33,216 Da. N-terminal sequencing was performed by Toray
Research Center, Inc, Tokyo, Japan.
ELISA assay for measuring the affinity of purified CD81
for HCV-E2. The ability of purified CD81 to bind to HCV-E2
was measured using ELISA. ELISA plates (96-well) were coated
with 100 ng of rho-1D4 antibody in PBS buffer (200 ml).
Following overnight incubation at 4uC, the unbound rho-1D4
antibody was removed by three washes, each with 200 ml TBS
buffer. All further steps were carried out at room temperature. To
minimize non-specific binding the wells were blocked with Ultra-
block for 2 hours. This was followed by addition of 100 ng of
purified CD81 (in buffer D containing 0.05% DM) to the wells,
following incubation for another 2 h; various concentrations of E2
glycoprotein from 0.4 to 20 nM (in buffer D containing 0.05%
DM) were now added to the wells and binding allowed to proceed
for another 2 h. Primary anti-E2 antibody at 1:2000 dilutions and
secondary antibody with alkaline phosphatase conjugate at 1:1000
dilutions were added followed by incubation for another 2 h.
Enzymatic color reaction was carried out using ELISA
amplification system following the manufacturers instructions.
Measurements were recorded at the absorbance of 495 nm by
Spectra MAX 340PC, Molecular Devices.
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Supporting Information
Figure S1 Nucleotide sequence of the codon-optimized CD81
gene, and the corresponding amino acid sequence. The locations
of the restriction sites EcoRI and NotI in the gene are shown
above the DNA sequence. The synthetic gene contains at its C-
terminus the rhodopsin C-terminal nonapeptide sequence (shown
underlined) to facilitate detection and purification of the protein
using the monoclonal antibody rho-1D4.
Found at: doi:10.1371/journal.pone.0002314.s001 (0.02 MB
DOC)
Figure S2 Quantitative CD81 receptor expressed in HEK293S-
TetR stable cell line. Left panel, Immunoblot analysis of CD81
using monoclonal antibody rho-1D4, the mobility of CD81
corresponded to a molecular mass of about 27kDa. The increasing
amounts of rhodopsin standards (ROS) allow determination of the
amount of CD81 expressed. Right panel, determination of CD81
expression by comparison to rhodopsin standards shown in the left
panel. By this method, the amount of rho-1D4 affinity purified
CD81 obtained was determined to be 2662 mg/36107 cells
(15 cm tissue culture plate).
Found at: doi:10.1371/journal.pone.0002314.s002 (0.23 MB TIF)
Table S1 PCR primers used for synthesis of the codon-
optimized CD81 gene. The sense strand (SS) and anti-sense
strand (AS) consist of 20 oligonucleotides each, and the sizes of the
primers in base pairs are indicated next to the sequence.
Found at: doi:10.1371/journal.pone.0002314.s003 (0.02 MB
DOC)
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